Mexico Pulmonary Arterial Hypertension Market Size & Outlook
Mexico pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Mexico pulmonary arterial hypertension market highlights
- The Mexico pulmonary arterial hypertension market generated a revenue of USD 176.4 million in 2023 and is expected to reach USD 263.8 million by 2030.
- The Mexico market is expected to grow at a CAGR of 5.9% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 176.4 million |
| Market revenue in 2030 | USD 263.8 million |
| Growth rate | 5.9% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Mexico accounted for 2.4% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 263.8 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.17% in 2023. Horizon Databook has segmented the Mexico pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is expected to exhibit lucrative CAGR during the forecast period. The country has efficient treatment options which prevent or respond rapidly to emergencies. If the global economic activity remains subdued specifically in developed countries, export instability in Mexico resulting in slows down of the manufacturing practices.
Thus, very slow growth is attributed in Mexico due to economic instability. According to WHO, in 2016, 10.4% of people were diabetic, while 63.4% were overweight. Such a high prevalence of diabetes and its associated factors may propel country’s market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Mexico Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
